Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib.

× No keyword cloud information.

18 in total

Review 1. Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review.

Authors: Bo Zhang; Yanwei Zhang; Jianlin Xu; Xueyan Zhang; Tianqing Chu; Shuyuan Wang; Jie Qian; Rong Qiao; Jun Lu; Lele Zhang; Baohui Han
Journal: Target Oncol Date: 2018-10 Impact factor: 4.493

2. A case of primary pulmonary atypical carcinoid with EML4-ALK rearrangement.

Authors: Na Liu; Jingjing Wang; Xiao Fu; Xiaoqiang Zheng; Huan Gao; Tao Tian; Zhiping Ruan; Yu Yao
Journal: Cancer Biol Ther Date: 2019-09-27 Impact factor: 4.742

3. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.

Authors: Natasha Rekhtman; Maria C Pietanza; Matthew D Hellmann; Jarushka Naidoo; Arshi Arora; Helen Won; Darragh F Halpenny; Hangjun Wang; Shaozhou K Tian; Anya M Litvak; Paul K Paik; Alexander E Drilon; Nicholas Socci; John T Poirier; Ronglai Shen; Michael F Berger; Andre L Moreira; William D Travis; Charles M Rudin; Marc Ladanyi
Journal: Clin Cancer Res Date: 2016-03-09 Impact factor: 12.531

4. A high-quality model for predicting the prognosis of breast neuroendocrine carcinoma to help clinicians decide on appropriate treatment methods: A population-based analysis.

Authors: Yu-Qiu Chen; Xiao-Fan Xu; Jia-Wei Xu; Tian-Yu Di; Xu-Lin Wang; Li-Qun Huo; Lu Wang; Jun Gu; Guo-Hua Zhou
Journal: Transl Oncol Date: 2022-06-11 Impact factor: 4.803

5. Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?

Authors: Birgitta Hiddinga; Karen Zwaenepoel; Annelies Janssens; Jan Van Meerbeeck; Patrick Pauwels
Journal: Oncotarget Date: 2022-06-01

Review 6. Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments.

Authors: Masayo Yoshimura; Kurumi Seki; Andrey Bychkov; Junya Fukuoka
Journal: Front Oncol Date: 2021-04-22 Impact factor: 6.244

7. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.

Authors: Ryohei Katayama; Takuya Sakashita; Noriko Yanagitani; Hironori Ninomiya; Atsushi Horiike; Luc Friboulet; Justin F Gainor; Noriko Motoi; Akito Dobashi; Seiji Sakata; Yuichi Tambo; Satoru Kitazono; Shigeo Sato; Sumie Koike; A John Iafrate; Mari Mino-Kenudson; Yuichi Ishikawa; Alice T Shaw; Jeffrey A Engelman; Kengo Takeuchi; Makoto Nishio; Naoya Fujita
Journal: EBioMedicine Date: 2015-12-12 Impact factor: 8.143

8. Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor.

Authors: Masayuki Nakajima; Naoki Uchiyama; Rie Shigemasa; Takeshi Matsumura; Ryota Matsuoka; Akihiro Nomura
Journal: Intern Med Date: 2016-11-01 Impact factor: 1.271

9. Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib.

Authors: Liping Lin; Fuxi Huang; Fang Chen; Yan He; Jiazhu Hu; Xiaolong Cao
Journal: J Int Med Res Date: 2018-01-08 Impact factor: 1.671

10. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.

Authors: Nobuyoshi Hayashi; Akihisa Fujita; Toyohiro Saikai; Hirotugu Takabatake; Mie Sotoshiro; Kyuutarou Sekine; Akihiko Kawana
Journal: Intern Med Date: 2017-11-20 Impact factor: 1.271